Samsung's Lee fined over illegally using propofol

Samsung’s de facto chief Lee Jae-yong has been fined 70 million won, or about $60,000, for illegally using the anesthetic drug propofol

Via AP news wire
Tuesday 26 October 2021 11:58
South Korea Samsung
South Korea Samsung

Samsung’s de facto chief Lee Jae-yong was fined 70 million won (about $60,000) on Tuesday for illegally using the anesthetic drug propofol, about two months after he was released on parole over a separate corruption case.

The Seoul Central District Court said it convicted Lee, vice chairman of Samsung Electronics, of violating a law on drug controls. It said Lee was also ordered to forfeit about 10 million won ($8,570).

Lee, who is the third-generation heir of South Korea's biggest company, Samsung, has been involved in a series of corruption cases lately. The company's crown jewel, Samsung Electronics, singlehandedly represents about 20% of South Korea’s entire stock market value and one-fourth of its total exports.

Prosecutors earlier accused Lee of taking propofol at a hospital in Seoul about 40 times for non-medical purposes. Lee’s lawyers said he took propofol in line with a doctor’s prescription, according to the court.

Propofol is used for anesthesia and sedation. Its use gained notoriety in 2009 when pop star Michael Jackson died of a propofol overdose.

In August, Lee was released from prison after serving 18 months of a 30-month sentence for embezzling millions of dollars from corporate funds to bribe then-President Park Geun-hye The bribery scheme was to ensure Geun-hye's support for a 2015 merger between two Samsung affiliates that tightened Lee's control over the corporate empire.

Lee is also facing a separate court trial over alleged stock price manipulation, auditing violations and other financial crimes related to the 2015 merger.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in